Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SRT-015
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Genfit
Deal Size : $106.8 million
Deal Type : Licensing Agreement
GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset
Details : Under the agreement, GENFIT has gained the exclusive worldwide rights of SRT-015, a highly optimized, first-in-class ASK1 inhibitor being developed in acute-on-chronic liver failure (ACLF), from Seal Rock Therapeutics.
Brand Name : SRT-015
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 31, 2023
Lead Product(s) : SRT-015
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Genfit
Deal Size : $106.8 million
Deal Type : Licensing Agreement
Lead Product(s) : SRT-015
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SRT-015 is a second generation apoptosis signal-regulating kinase (ASK1) inhibitor for treatment of alcoholic hepatitis, non-alcoholic steatohepatitis (NASH) and other liver diseases.
Brand Name : SRT-015
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 24, 2022
Lead Product(s) : SRT-015
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SRT-015
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The presentations demonstrate superior pharmacological properties of SRT-015 compared to other ASK1 inhibitors, including selonsertib, and provide potential explanations for the failure of selonsertib in clinical trials.
Brand Name : SRT-015
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 16, 2020
Lead Product(s) : SRT-015
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SRT-015
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Seal Rock Therapeutics Announces Upcoming Presentations at AASLD's The Liver Meeting® 2020
Details : Posters to highlight excellent efficacy of SRT-015 in NASH-relevant models, and comparator data with the ASK1 inhibitor selonsertib that is consistent with its lack of efficacy in phase 3 trials.
Brand Name : SRT-015
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 02, 2020
Lead Product(s) : SRT-015
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?